

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655

Attorney Docket No. Q58513

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (canceled).
2. (canceled).
3. (canceled).
4. (canceled).
5. (canceled).
6. (canceled).
7. (canceled).
8. (canceled).
9. (canceled).
10. (canceled).
11. (canceled).
12. (canceled).
13. (canceled).
14. (canceled).
15. (canceled).
16. (canceled).
17. (canceled).

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655

Attorney Docket No. Q58513

18. (canceled).

19. (canceled).

20. (canceled).

21. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-prostaglandin compound.

22. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 15-keto-16-mono or dihalogen-prostaglandin compound.

23. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or di-halogen-prostaglandin compound.

24. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 15-keto-16-mono or di-fluoro-prostaglandin compound.

25. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or di-fluoro-prostaglandin compound.

26. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 15-keto-20-lower alkyl-prostaglandin compound.

27. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 15-keto-20-ethyl-prostaglandin compound.

28. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 2-decarboxy-2-(2-carboxy lower alkyl)-15-keto-prostaglandin compound.

29. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-15-keto-prostaglandin compound.

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655

Attorney Docket No. Q58513

30. (previously presented): The method of claim 41, wherein the 15-keto-prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16-mono or di-fluoro prostaglandin compound.

31. (previously presented): The method of claim 41, wherein the 15-keto prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16-mono or di-fluoro-20-ethyl-prostaglandin compound.

32. (previously presented): The method of claim 41, wherein the 15-keto prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-di-fluoro-20-ethyl-prostaglandin compound.

33. (previously presented): The method of claim 41, wherein the 15-keto prostaglandin compound is a 15-keto-prostaglandin E compound.

34. (previously presented): The method of claim 41, wherein the 15-keto prostaglandin compound is a 2-decarboxy-2-(2-carboxyethyl)-13,14-dihydro-15-keto-16,16-di-fluoro-20-ethyl-prostaglandin E₁ isopropyl ester.

35. (canceled).

36. (canceled).

37. (canceled).

38. (previously presented): The method of claim 41, which comprises administering ophthalmically a composition comprising a 15-keto-prostaglandin compound formulated in a dosage form suitable for ophthalmic administration.


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655

Attorney Docket No. Q58513

39. (previously presented): The method of claim 38, wherein said composition is formulated as eye drops.

40. (canceled).

41. (previously presented): A method for treating photoreinitis in a subject, which comprises administering an effective amount of a 15-keto prostaglandin compound represented by the following formula (II):



wherein L and M are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, hydroxy(lower)alkyl or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have one or more double bond;

A is $-\text{CH}_2\text{OH}$, $-\text{COCH}_2\text{OH}$, $-\text{COOH}$ or its functional derivative;

B is $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$;

X_1 and X_2 are hydrogen, lower alkyl or halogen;

R_1 is a divalent saturated or unsaturated lower-medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group;

R_2 is a single bond or lower alkylene; and


R_3 is lower alkyl, lower alkoxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group to the subject.

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Application No. 09/816,655

Attorney Docket No. Q58513

42. (canceled).

43. (new): A method for treating light induced retinal photic injury in a subject, which comprises administering an effective amount of a 15-keto prostaglandin compound represented by the following formula (II):



wherein L and M are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, hydroxy(lower)alkyl or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have one or more double bond;

A is -CH₂OH, -COCH₂OH, -COOH or its functional derivative;

B is -CH₂-CH₂-, -CH=CH- or -C≡C-;

X₁ and X₂ are hydrogen, lower alkyl or halogen;

R₁ is a divalent saturated or unsaturated lower-medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group;

R₂ is a single bond or lower alkylene; and

R₃ is lower alkyl, lower alkoxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group

to the subject.